On April 27, 2017 Kyowa Hakko Kirin Co., Ltd., an R&D-based life sciences company with special strengths in biotechnology, reported financial results for the first quarter ended March 31, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Net worldwide sales for the first quarter of 2017 were 90.9 billions of yen in comparison to that of 88.4 billions of yen for the first quarter of 2016. Regional Sales for the first quarter of 2017 were as follows: Japan 60.1 bn yen, Americas 7.5 bn yen, Europe 15.8 bn yen, Asia, 7.1 bn yen and other regions amounted to 0.2 bn yen.

For Kyowa Hakko Kirin Co., Ltd’s detailed sales figures, visit: View Source